Could an HIV drug calm brain inflammation in Alzheimer's? new study aims to find out
NCT ID NCT07553338
First seen May 06, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tests whether the drug leronlimab is safe for people with mild Alzheimer's or mild cognitive impairment (MCI) due to Alzheimer's. It also looks at whether the drug can reduce brain inflammation, which is thought to play a role in the disease. Twenty volunteers aged 50 and older will receive weekly injections for 12 weeks, along with brain scans and memory tests. This is an early-stage trial focused on safety and biological effects, not yet on improving thinking or memory.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine Brain Health Imaging Institute
New York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.